Results 51 to 60 of about 2,193 (158)

The pipeline of new molecules and regimens against drug-resistant tuberculosis

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021
The clinical development and regulatory approval of bedaquiline, delamanid and pretomanid over the last decade brought about significant progress in the management of drug-resistant tuberculosis, providing all-oral regimens with favorable safety profiles.
Todd A. Black, Ulrike K. Buchwald
doaj   +1 more source

Randomized, Placebo‐Controlled, First‐in‐Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy Adults

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract This first‐in‐human study (ClinicalTrials.gov identifier: NCT04472897) evaluated the safety, tolerability, pharmacokinetics, and food effect of single ascending and repeat oral doses of GSK2556286 (GSK286), a novel antitubercular drug candidate with efficacy in animal models of tuberculosis.
Emma Ilsley, Edward Banham‐Hall, Tetyana Chaychenko, Katerina Chinenyeze, Gareth Maher‐Edwards, Catherine Muya, Katie Rolfe, Raman Sharma, Simon Tiberi, David Barros‐Aguirre   +9 more
wiley   +1 more source

An Interactive Pharmacokinetic‐Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Bedaquiline is approved for use in a thrice‐weekly dosing schedule; simpler once‐daily dosing strategies could enable fixed‐dose combinations and improve patient adherence. We developed an interactive R Shiny simulation tool to enable the evaluation of different bedaquiline dosing schedules within an integrated dose‐pharmacokinetic‐efficacy ...
Yu‐Jou Lin, Frances Okibedi, Mats O. Karlsson, Elin M. Svensson   +3 more
wiley   +1 more source

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, Volume 15, Issue 14, 10 April 2026.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source

Improving Genotype Imputation in High‐Dimensional Pharmacogenomics Using Multiple Imputation: Evaluation with Machine Learning Approaches

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 964-978, April 2026.
Multiple imputation is well‐established for handling missing data, yet its use in high‐dimensional genetic datasets remains limited. Using pharmacokinetic tuberculosis simulations and SNP data (1000 Genomes Project), we compared machine learning (ML) and traditional approaches (e.g., mean imputation and complete‐case analysis) for imputation and ...
Innocent G. Asiimwe, Tao You, Daniel F. Carr, Munir Pirmohamed, Geraint Davies, Andrea L. Jorgensen, on behalf of the UNITE4TB Consortium   +6 more
wiley   +1 more source

Exploring Novel Nitrofuryl‐1,3,4‐Thiadiazole‐Based Derivatives: Design, Synthesis, and Evaluation of In Vitro Leishmanicidal and Trypanocidal Activity

Archiv der Pharmazie, Volume 359, Issue 3, March 2026.
In a series of substituted 1‐[5‐(5‐nitrofuran‐2‐yl)‐1,3,4‐thiadiazol‐2‐yl]piperidine‐4‐carboxamides evaluated for in vitro antileishmanial and antitrypanosomal activity, compound 18 emerged as the most promising derivative, showing submicromolar anti‐parasitic effects targeting diverse Leishmania and Trypanosoma species and acceptable selectivity ...
Alireza Mousavi, Martina Slapničková, Maryam Norouzbahari, Sarah D'Alessandro, Parham Foroumadi, Fariba Peytam, Federica Perego, Eva Doleželová, Zahra Emamgholipour, Maliheh Barazandeh Tehrani, Seyed Esmaeil Sadat‐Ebrahimi, Elahe Hosseinzadeh, Elmira Meghrazi Ahadi, Loghman Firoozpour, Hamidreza Bijanzadeh, Nicoletta Basilico, Alena Zíková, Alireza Foroumadi   +17 more
wiley   +1 more source

A 9‐Year‐Old Boy With Right‐Sided Extrapulmonary Drug‐Resistant Tuberculosis Subphrenic Abscess: A Case Report From Woldia, Northeast Ethiopia

Clinical Case Reports, Volume 14, Issue 3, March 2026.
Coronal reconstruction post contrast thoraco‐abdominal CT of a 9 years old boy taken December, 2023. This shows 1.45 by 3.9 cms hypodense collection having rim enhancement in the right anterio‐inferior sub‐phrenic space suggestive of abscess. ABSTRACT Diagnosing extrapulmonary and drug‐resistant tuberculosis in children is challenging.
Animaw Lingerew, Samuel Addis, Adugnaw Atnafu, Zeru Siyoum, Solomie Jebessa Deribessa   +4 more
wiley   +1 more source

Free Radical Production Induced by Nitroimidazole Compounds Lead to Cell Death in Leishmania infantum Amastigotes

Molecules
Leishmania infantum is the vector-borne trypanosomatid parasite causing visceral leishmaniasis in the Mediterranean basin. This neglected tropical disease is treated with a limited number of obsolete drugs that are not exempt from adverse effects and ...
Julia Andrés-Rodríguez, María-Cristina González-Montero, Nerea García-Fernández, Estefanía Calvo-Álvarez, María-Yolanda Pérez-Pertejo, Rosa-María Reguera-Torres, Rafael Balaña-Fouce, Carlos García-Estrada   +7 more
doaj   +1 more source

Activity Profiling of Nitro‐Substituted Di(Hetero)Aryl 1,3,4‐ and 1,2,4‐Oxadiazoles: Antimicrobial, Cholinesterase Inhibition and Antioxidant Potential

Archiv der Pharmazie, Volume 359, Issue 1, January 2026.
Novel nitro‐substituted diaryl 1,3,4‐ and 1,2,4‐oxadiazoles were synthesised via molecular hybridisation of bioactive heterocycles. Selected derivatives exhibited potent antimicrobial activity, including against Mycobacterium tuberculosis and Staphylococcus aureus, and cholinesterase inhibitory activity, with promising selectivity.
Enikő Šikorová, Šárka Štěpánková, Eva Frýbová, Klára Konečná, Jana Korbielová, Markéta Švarcová, Ondřej Janďourek, Václav Pflégr, Szilvia Bősze, Martin Krátký   +9 more
wiley   +1 more source

Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines

IJTLD Open
BACKGROUND: In 2022, the WHO announced that the 6-month BPaL/M regimen should be used for drug-resistant TB (DR-TB). We estimate the patient and provider costs of BPaL compared to current standard-of-care treatment in the Philippines.METHODS: Patients on
D. Evans, K. Hirasen, D.J. Casalme, M.T. Gler, A. Gupta, S. Juneja   +5 more
doaj   +1 more source